Navidea Biopharmaceuticals Enters into Option Agreement to License Parkinson’s Disease Imaging Agent

  – Licensing would add second neuro-imaging candidate to growing Navidea Biopharmaceuticals pipeline – DUBLIN, Ohio — 01/25/2012 (CRWENEWSWIRE) — Navidea Biopharmaceuticals, Inc. (NYSE Amex:NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IAFCT Injection, also called [...]